ArticleCell death & disease2014
PlGF-MMP9-engineered iPS cells supported on a PEG-fibrinogen hydrogel scaffold possess an enhanced capacity to repair damaged myocardium.
Article in Cell death & disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Advances and Prospects in Using Induced Pluripotent Stem Cells for 3D Bioprinting in Cardiac Tissue Engineering.Reviews in cardiovascular medicine · 2025Pooled it
- Fibrin scaffolds for angiogenesis in soft tissue models: a systematic review.Bioactive materials · 2026Review
- Key Steps in Murine Cardiac Engineering Validation: How Does It Affect the Efficiency of Cardiac Devices?BioMed research international · 2026Review
- Integrative analysis of genes reveals endoplasmic reticulum stress-related immune responses involved in dilated cardiomyopathy with fibrosis.Apoptosis : an international journal on programmed cell death · 2023Article
- A combined cell and growth factor delivery for the repair of a critical size tibia defect using biodegradable hydrogel implants.Journal of tissue engineering and regenerative medicine · 2022Article
- Reconstructing the heart using iPSCs: Engineering strategies and applications.Journal of molecular and cellular cardiology · 2021Review
- Polymeric Biomaterials for the Treatment of Cardiac Post-Infarction Injuries.Pharmaceutics · 2021Review
- Maturation strategies and limitations of induced pluripotent stem cell-derived cardiomyocytes.Bioscience reports · 2021Review
- Recapitulating Cardiac Structure and Function In Vitro from Simple to Complex Engineering.Micromachines · 2021Review
- Article
- Biodegradable Nanopolymers in Cardiac Tissue Engineering: From Concept Towards Nanomedicine.International journal of nanomedicine · 2020Review
- Nanoparticles as Versatile Tools for Mechanotransduction in Tissues and Organoids.Frontiers in bioengineering and biotechnology · 2020Review
- The Potential of Stem Cells and Stem Cell-Derived Exosomes in Treating Cardiovascular Diseases.Journal of cardiovascular translational research · 2019Review
- Encapsulation of macrophages enhances their retention and angiogenic potential.NPJ Regenerative medicine · 2019Article
- A multi-cellular 3D bioprinting approach for vascularized heart tissue engineering based on HUVECs and iPSC-derived cardiomyocytes.Scientific reports · 2018Article
- Application of Composite Hydrogels to Control Physical Properties in Tissue Engineering and Regenerative Medicine.Gels (Basel, Switzerland) · 2018Review
- Givinostat reduces adverse cardiac remodeling through regulating fibroblasts activation.Cell death & disease · 2018Article
- Optimal Environmental Stiffness for Stem Cell Mediated Ischemic Myocardium Repair.Methods in molecular biology (Clifton, N.J.) · 2017Review
- Direct hydrogel encapsulation of pluripotent stem cells enables ontomimetic differentiation and growth of engineered human heart tissues.Biomaterials · 2016Article
- Engineered Vascularized Muscle Flap.Journal of visualized experiments : JoVE · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell-based regenerative therapies are significantly improved by engineering allografts to express factors that increase vascularization and engraftment, such as placental growth factor (PlGF) and matrix metalloproteinase 9 (MMP9). Moreover, the seeding of therapeutic cells onto a suitable scaffold is of utmost importance for tissue regeneration. On these premises, we sought to assess the reparative potential of induced pluripotent stem (iPS) cells bioengineered to secrete PlGF or MMP9 and delivered to infarcted myocardium upon a poly(ethylene glycol)-fibrinogen scaffold. When assessing optimal stiffness of the PEG-fibrinogen (PF) scaffold, we found that the appearance of contracting cells after cardiogenic induction was accelerated on the support designed with an intermediate stiffness. Revascularization and hemodynamic parameters of infarcted mouse heart were significantly improved by injection into the infarct of this optimized PF scaffold seeded with both MiPS (iPS cells engineered to secrete MMP9) and PiPS (iPS cells engineered to secrete PlGF) cells as compared with nonengineered cells or PF alone. Importantly, allograft-derived cells and host myocardium were functionally integrated. Therefore, survival and integration of allografts in the ischemic heart can be significantly improved with the use of therapeutic cells bioengineered to secrete MMP9 and PlGF and encapsulated within an injectable PF hydrogel having an optimized stiffness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.